Quick Answer
Ascendis Pharma A/S reported Total Assets of $1.30 billion for fiscal year 2025.
Ascendis Pharma A/S — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $1.30B +10.4% |
$1.18B +42.9% |
$825.59M -24.2% |
$1.09B +0.4% |
$1.08B +10.7% |
$979.79M +44.8% |
| R&D Expense | $303.62M -1.1% |
$307.00M -25.7% |
$413.45M +8.9% |
$379.62M +28.3% |
$295.87M +13.4% |
$260.90M +36.2% |
| Gross Profit | $625.22M +95.8% |
$319.38M +43.7% |
$222.32M +469.5% |
$39.04M +817.4% |
$4.25M -38.8% |
$6.95M -48.0% |
- Ascendis Pharma A/S reported Total Assets of $1.30 billion for fiscal year 2025.
- Ascendis Pharma A/S showed an increase of +10.4% in Total Assets compared to the prior fiscal year.
- Ascendis Pharma A/S reported R&D Expense of $303.62 million for fiscal year 2025.
- Ascendis Pharma A/S showed a decrease of -1.1% in R&D Expense compared to the prior fiscal year.
- Ascendis Pharma A/S reported Gross Profit of $625.22 million for fiscal year 2025.
- Ascendis Pharma A/S showed an increase of +95.8% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: